CytoMed <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Submits Cash Bid to Acquire <a href="https://laohu8.com/S/TCBP">TC BioPharm</a> Assets
CytoMed Therapeutics Limited has submitted a cash bid to acquire selected assets of TC BioPharm Limited, following the appointment of joint administrators to TC BioPharm earlier this month. Both companies focus on developing donor-derived allogeneic gamma delta T cell therapies for cancer treatment. CytoMed recently completed an acquisition of a licensed cord blood bank in Malaysia and aims to leverage these assets to accelerate its development of affordable cell-based immunotherapies for cancer and autoimmune diseases. The company believes the addition of TC BioPharm's assets will strengthen its expertise in allogeneic cell therapies and support its mission to provide new therapeutic options for patients with unmet medical needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544979-en) on October 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。